Trial · NCT02964507
Results by group318
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 318
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | Non-serious AEs | 33 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | Non-serious AEs | 12 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | Non-serious AEs | 42 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | Non-serious AEs | 7 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 80mg + FUL 500 mg (AI Failure) | Non-serious AEs | 18 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 80 mg + FUL 500 mg (CDK4/6+AI Failure) | Non-serious AEs | 11 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | SAEs | 5 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | SAEs | 1 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | SAEs | 10 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | SAEs | 3 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 80mg + FUL 500 mg (AI Failure) | SAEs | 6 | Participants | |
| Phase I: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase I-GSK525762 80 mg + FUL 500 mg (CDK4/6+AI Failure) | SAEs | 2 | Participants | |
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | 2 | Participants | ||
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | 0 | Participants | ||
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+ AI Failure >= 12M) | 1 | Participants | ||
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 60+FUL500mg CDK4/6+AI Failure>=12M Bone Only Disease | 1 | Participants | ||
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 80mg + FUL 500 mg (AI Failure) | 0 | Participants | ||
| Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase I-GSK525762 80 mg + FUL 500 mg (CDK4/6+AI Failure) | 2 | Participants | ||
| Phase I: Number of Participants With Dose Reductions and Dose Interruption/Delays | Phase I-GSK525762 60 mg+FUL 500 mg (AI Failure) | Dose reduction | 9 | Participants | |
| Phase I: Number of Participants With Dose Reductions and Dose Interruption/Delays | Phase I-GSK525762 60 mg+FUL 500 mg (CDK4/6+AI Failure <12M) | Dose reduction | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964507/results